These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 31261371)

  • 41. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial.
    Man WH; Scheltema NM; Clerc M; van Houten MA; Nibbelke EE; Achten NB; Arp K; Sanders EAM; Bont LJ; Bogaert D
    Lancet Respir Med; 2020 Oct; 8(10):1022-1031. PubMed ID: 32203712
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of a Novel Palivizumab Prophylaxis Protocol for Respiratory Syncytial Virus Infection in Congenital Heart Disease: A Multicenter Study.
    Chiu SN; Wang JN; Fu YC; Chung HT; Chang LY; Wu MH; Hua YC; Lin MT; Lu CW; Chen CA; Wu JM; Wang JK
    J Pediatr; 2018 Apr; 195():108-114.e1. PubMed ID: 29395174
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The 2014-2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States.
    Kong AM; Krilov LR; Fergie J; Goldstein M; Diakun D; Wade SW; Pavilack M; McLaurin KK
    Am J Perinatol; 2018 Jan; 35(2):192-200. PubMed ID: 28881376
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
    Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A
    Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hospitalization for lower respiratory tract disease in preterm infants: effects of prophylaxis with palivizumab.
    Faldella G; Alessandroni R; Aquilano G; Vandini S; Lanari M; Silvestri M; Pistorio A; Rossi GA
    J Chemother; 2010 Feb; 22(1):30-5. PubMed ID: 20227990
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.
    Heikkinen T; Valkonen H; Lehtonen L; Vainionpää R; Ruuskanen O
    Arch Dis Child Fetal Neonatal Ed; 2005 Jan; 90(1):F64-8. PubMed ID: 15613580
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.
    Joffe S; Ray GT; Escobar GJ; Black SB; Lieu TA
    Pediatrics; 1999 Sep; 104(3 Pt 1):419-27. PubMed ID: 10469764
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Severe respiratory syncytial virus bronchiolitis: epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasia.
    Grimaldi M; Gouyon B; Michaut F; Huet F; Gouyon JB;
    Pediatr Infect Dis J; 2004 Dec; 23(12):1081-5. PubMed ID: 15626942
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of palivizumab prophylaxis among infants with congenital heart disease: A case control study.
    Ozyurt A; Narin N; Baykan A; Argun M; Pamukcu O; Zararsiz G; Sunkak S; Uzum K
    Pediatr Pulmonol; 2015 Oct; 50(10):1025-32. PubMed ID: 25156973
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis.
    Krilov LR; Masaquel AS; Weiner LB; Smith DM; Wade SW; Mahadevia PJ
    BMC Pediatr; 2014 Oct; 14():261. PubMed ID: 25308481
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
    Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
    Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Palivizumab efficacy in preterm infants with gestational age < or = 30 weeks without bronchopulmonary dysplasia.
    Grimaldi M; Gouyon B; Sagot P; Quantin C; Huet F; Gouyon JB;
    Pediatr Pulmonol; 2007 Mar; 42(3):189-92. PubMed ID: 17243184
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes.
    Oh PI; Lanctôt KL; Yoon A; Lee DS; Paes BA; Simmons BS; Parison D; Manzi P;
    Pediatr Infect Dis J; 2002 Jun; 21(6):512-8. PubMed ID: 12182374
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Systematic Review of the Safety and Efficacy of Palivizumab among Infants and Young Children with Cystic Fibrosis.
    Kua KP; Lee SWH
    Pharmacotherapy; 2017 Jun; 37(6):755-769. PubMed ID: 28423192
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Palivizumab for Infants < 29 Weeks in Hong Kong without a Clear-Cut Season for Respiratory Syncytial Virus Infection-A Cost-Effectiveness Analysis.
    Lee SR; Kwok KL; Ng DKK; Hon KL
    J Trop Pediatr; 2018 Oct; 64(5):418-425. PubMed ID: 29106671
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of the Withdrawal of Palivizumab Immunoprophylaxis on the Incidence of Respiratory Syncytial Virus (RSV) Hospitalizations Among Infants Born at 33 to 35 Weeks' Gestational Age in the Province of Quebec, Canada: The RSV-Quebec Study.
    Papenburg J; Defoy I; Massé E; Caouette G; Lebel MH
    J Pediatric Infect Dis Soc; 2021 Apr; 10(3):237-244. PubMed ID: 32530035
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?
    Geskey JM; Ceneviva GD; Brummel GL; Graff GR; Javier MC
    Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Respiratory syncytial virus acute respiratory infection-associated hospitalizations in preterm Mexican infants: A cohort study.
    Benítez-Guerra D; Piña-Flores C; Zamora-López M; Escalante-Padrón F; Lima-Rogel V; González-Ortiz AM; Guevara-Tovar M; Bernal-Silva S; Benito-Cruz B; Castillo-Martínez F; Martínez-Rodríguez LE; Ramírez-Ojeda V; Tello-Martínez N; Lomelí-Valdez R; Salto-Quintana J; Cadena-Mota S; Noyola DE
    Influenza Other Respir Viruses; 2020 Mar; 14(2):182-188. PubMed ID: 31917902
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Update on respiratory syncytial virus hospitalizations among U.S. preterm and term infants before and after the 2014 American Academy of Pediatrics policy on immunoprophylaxis: 2011-2017.
    Fergie J; Goldstein M; Krilov LR; Wade SW; Kong AM; Brannman L
    Hum Vaccin Immunother; 2021 May; 17(5):1536-1545. PubMed ID: 33090914
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Respiratory Syncytial Virus Related Readmission in Preterm Infants Less than 34 weeks' Gestation Following Discharge from a Neonatal Intensive Care Unit in Korea.
    Lee JH; Kim CS; Chang YS; Choi JH;
    J Korean Med Sci; 2015 Oct; 30 Suppl 1(Suppl 1):S104-10. PubMed ID: 26566351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.